Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

The GLP-1 receptor antagonist exendin(9-39)NH2 (ex9-39) was used to further explore the role of GLP-1 as an endogenous satiation signal.

Why It Was Studied

Exogenous glucagon-like peptide-1 (GLP-1) inhibits eating in healthy, overweight, and diabetic subjects.

Who Took Part

The abstract describes 10 men taking part.

By PubMed's age tags, the people studied were teenagers, young adults and adults, men only.

Two double-blind, 4-way crossover studies were performed, each of which included 10 healthy men.

In study A, subjects received an intravenous infusion of ex9-39 or saline plus an oral glucose preload and an intraduodenal infusion of saline or glucose for 60 min.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the men and researchers unaware of who received Glucagon.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

In study B, intravenous infusions were identical, but an oral mixed-liquid meal preload and a 60-min intraduodenal infusion of saline or oleic acid were administered.

Thirty minutes after oral preloads, subjects ate and drank ad libitum, and amounts ingested and the time to meal completion were quantified.

In addition, appetite and plasma GLP-1, peptide YY (PYY), insulin, glucagon, and blood glucose concentrations were measured.

What Was Measured

PubMed files the paper under topics including Appetite, Appetite Depressants, Drinking Behavior, Energy Intake, Feeding Behavior, Glucagon and Glucagon-Like Peptide 1.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon in 10 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (The American journal of clinical nutrition), a journal based in United States.

More context: the Glucagon compound page, all human trials.